Latham BioPharm Group
Latham BioPharm Group (LBG), now part of Sia Partners, is a consulting firm that provides specialized expertise across various life sciences sectors. The company is dedicated to helping innovative life sciences companies overcome complex scientific and business challenges. LBG offers a client-centric approach, adapting to the strategic direction and objectives of its clients to deliver meaningful analysis and quantifiable results. The firm is known for its scalable and flexible solutions that advance products and programs in the life sciences industry.
What We Do
LBG consultants provide insight, knowledge, and network connections to match programs with appropriate government agencies and opportunities, helping clients navigate the funding process.
LBG offers expertise across all functional product development disciplines for vaccines, therapeutics, cell and gene therapies, and medical devices and diagnostics.
LBG supports pipeline and portfolio review, market research, asset opportunity analysis, due diligence, and financial modeling, among other strategic consulting services.
Biologics
Digital Health Technologies
Show More (3)Key People
Principal Consultant 1
Senior Consultant
Senior Analyst
Managing Director
Consultant 3
Associate Manager
News & Updates
Patrick Falvey, Principal Consultant at LBG, was featured in the American Pharmaceutical Review for his expertise on global biomanufacturing trends.
An article discussing the potential of cytokines in cancer immunotherapy, focusing on the research of SON-1010, an albumin-binding IL-12 fusion protein.
LBG has been awarded a grant to develop a platform for global health cost modeling.
Public Health Vaccines has initiated the first clinical trial for its Marburg virus vaccine.
LBG has been awarded a contract by NIAID for preclinical services, valued at up to $30 million.